Certolizumab pegol

WikiDoc Resources for Certolizumab pegol
Articles
Most recent articles on Certolizumab pegol Most cited articles on Certolizumab pegol Review articles on Certolizumab pegol Articles on Certolizumab pegol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Certolizumab pegol Images of Certolizumab pegol Photos of Certolizumab pegol Podcasts & MP3s on Certolizumab pegol Videos on Certolizumab pegol
Evidence Based Medicine
Cochrane Collaboration on Certolizumab pegol Bandolier on Certolizumab pegol TRIP on Certolizumab pegol
Clinical Trials
Ongoing Trials on Certolizumab pegol at Clinical Trials.gov Trial results on Certolizumab pegol Clinical Trials on Certolizumab pegol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Certolizumab pegol NICE Guidance on Certolizumab pegol NHS PRODIGY Guidance FDA on Certolizumab pegol CDC on Certolizumab pegol
Books
Books on Certolizumab pegol
News
Certolizumab pegol in the news Be alerted to news on Certolizumab pegol News trends on Certolizumab pegol
Commentary
Blogs on Certolizumab pegol
Definitions
Definitions of Certolizumab pegol
Patient Resources / Community
Patient resources on Certolizumab pegol Discussion groups on Certolizumab pegol Patient Handouts on Certolizumab pegol Directions to Hospitals Treating Certolizumab pegol Risk calculators and risk factors for Certolizumab pegol
Healthcare Provider Resources
Symptoms of Certolizumab pegol Causes & Risk Factors for Certolizumab pegol Diagnostic studies for Certolizumab pegol Treatment of Certolizumab pegol
Continuing Medical Education (CME)
CME Programs on Certolizumab pegol
International
Certolizumab pegol en Espanol Certolizumab pegol en Francais
Business
Certolizumab pegol in the Marketplace Patents on Certolizumab pegol
Experimental / Informatics
List of terms related to Certolizumab pegol

Overview

Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody.

It is the subject of phase III clinical trials in both Crohn's disease and rheumatoid arthritis.

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.

In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.

External links

• certolizumab+pegol at the US National Library of Medicine Medical Subject Headings (MeSH)